$800 – $1,600

Biopharma Sustainability Roundtable 2019

Event Information

Share this event

Date and Time



Merck & Co.

2000 Galloping Hill Road

Kenilworth, NJ 07033

View Map

Refund Policy

Refund Policy

Refunds up to 30 days before event

Event description


Biopharma Sustainability Roundtable

Tue-Wed, April 9-10 — Merck & Co., Kenilworth NJ

Our 7th annual Biopharma Sustainability Roundtable, will be hosted by Merck & Co. at their Kenilworth HQ. The Roundtable is unique in focusing deeply on a single industry while addressing the full range of sustainability concerns, from the strategic and conceptual to day-to-day operations. Interactive seminar-style discussions among senior executives and industry experts are challenging and frank, held under the Chatham House Rule.

This year our focus is on themes of sustainability and access strategy, corporate governance, and effective communication of material ESG performance topics with investors and other stakeholders.

Day 1 opens with a discussion of our pre-Roundtable Sustainability Survey results, and participants' top sustainability challenges for 2019. Carmen Villar, VP for Social Business Innovation at Merck will open the meeting, and presentations in development include:

  • Key takeaways from our ESG Communications Initiative will be shared by Matt Goldman, Sr. Manager for CSR & Sustainability, Amgen, and Chris Pinney, CEO of our co-Sponsor, the High Meadows Institute.
  • Christina Wong, Director at SustainAbility (ERM), will share insights from their recently updated international ‘Rate the Raters’ survey.
  • Michael Fürst, Head of Social Innovation & Strategy at Novartis, will discuss the conduct and outcomes of their recent strategic materiality review.

The Tuesday evening networking reception, keynote, and dinner will be held at the nearby Galloping Hill Golf Course. Helen Routh, previously Head of Integrated Solutions and Sr. VP of Strategy & Innovation at Philips, now a healthcare and IT consultant, will address the promise and risk of real-world data, analytics, personalization, and AI in healthcare.

Day 1 Guest Participants

Day 2 shifts the focus from strategy to implementation, with topics including:

  • Case study of impact investing as a new tool for biopharma sustainability, with Ken Gustavsen, Exec. Director of CR, Merck, and Saqib Rashid, Head of Investor Relations, Leapfrog Investments.
  • Exploring biopharma futures through scenario planning with Alison Taylor, Managing Director for Sustainability Management at BSR, and regulatory monitoring with Olivier Jaeggi, Managing Director & Chairman at ECOFACT.
  • Karin Steinmann, Health Policy Lead for for Global Institutions, Amgen, will lead a deep dive into the connections between access to healthcare and business strategy.
  • Outcome metrics for access to medicines will be discussed by Prof. Peter Rockers from the Boston University School of Public Health, including work being done in collaboration with the UNGC Access Accelerated program.
  • Recent research on the future of drug pricing and innovative biopharma business models will be shared by David Song, Managing Director & Healthcare Portfolio Manager, and Rolando Morillo, VP & ESG Equity Analyst, both with Rockefeller Capital Management.
  • We'll finish the day with brief case studies on best practices insustainability governance, including an update from Cora Olsen, Global Lead for Integrated Reporting at Novo Nordisk on their work with Future Fit for goal setting and performance management.

The Roundtable wraps up with a late-afternoon networking reception.

Guest Participants Day 2

Biopharma Investor Day

Thu April 11 — BlackRock, New York NY

We’re excited to welcome BlackRock as a new sponsor and host of our 5th annual Investor Day in Manhattan. The Investor Day brings together sustainability leaders from both biopharma and the investment community for a focused and direct conversation that complements but is independent from the previous two days at the Biopharma Sustainability Roundtable.

This year we’ll be addressing the wave of interest in more effective ESG reporting and investor engagement with a deep dive into key alignments and mis-alignments between investors and biopharma corporates on the highest priority material issues and most effective communication methods. To encourage frank interchange, our discussions are conducted under the Chatham House rule for collegial discretion, and no 3rd-parties (reporting, rating, ranking, or consulting) will particiapte.

  • Danielle Sugarman, VP Investment Stewardship & Biopharma Sector Lead for BlackRock, will discuss their approach to industry engagement, and issues to address in the biopharma conversation.
  • We'll share and seek feedback on initial results from our ESG Communications Initiative. Key takeaways from the biopharma perspective will be shared by Matt Goldman, Sr. Manager for CSR & Sustainability, Amgen. Chris Pinney, CEO of our co-Sponsor, the High Meadows Institute, will address the investor's perspective as part of HMI’s Institutional Investor-Industry Engagement project.
  • Unique industry insights for investors from the Biopharma Sustainability Roundtable discussions, highlighting industry best practices in strategic materiality assessment, access to medicines, drug pricing, and governance.
  • Facilitated discussion to explore how we can move forward to address the highest priority ESG concerns jointly identified by both investors and biopharmas.

A mid-afternoon networking reception will wrap-up the day.

BSRT 2019 Sponsor Banner


There is a diverse and interconnected community of interest around sustainability, so companies are encouraged to send more than one participant to represent related functional areas, increasing the mix of perspectives and depth of experience for everyone at the Roundtable.

Who should come? By role, past attendees have included: CSO, VP Facilities & Engineering, Director EHS, Director Capital Planning, Sr. Manager Asset Management, Sr. Director Risk Management, VP Technical Operations, Director Sustainability, Director of Investor Relations, and Head of Corporate Responsibility.

Previous and expected new participants this year include:

  • Amgen
  • Alkermes
  • AstraZeneca (MedImmune)
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Ferring Pharma
  • Lonza
  • Merck & Co.
  • Merck KGaA
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Roche (Genentech)
  • Sanofi (Genzyme)
  • Takeda (Shire)
  • UCB Pharma

Investor community:

  • Arabesque
  • Bank J. Safra Sarasin
  • BlackRock
  • Chardan Capital Markets
  • Cornerstone Capital
  • Domini Social Investments
  • MSCI
  • Rockefeller Capital Management
  • SICM
  • UBS

We also invite a range of non-Biopharma organizations to join the conversation, this year including:

  • Business for Social Responsibility (BSR)
  • Eco:Fact
  • High Meadows Institute
  • KKS Advisors
  • Leapfrog Investments
  • SASB
  • SustainAbility (ERM)


Schedule: The Roundtable will be Tuesday-Wednesday, April 9-10, 2019, from 8:30 am to 4:00 pm at Merck & Co. in Kenilworth NJ. The Roundtable includes a keynote reception and dinner on Tuesday evening the 9th at the Galloping Hill Golf Course, and a brief wrap-up reception on Wednesday the 10th. A focused Investor Dialog follows on Thursday April 11, from 8:30 am to 3:00 pm at BlackRock, nearby in New York City.

Registration: Registration for each event is separate, and includes breakfast, lunch, and closing receptions. Roundtable registration also includes the Tuesday evening keynote reception and dinner. Travel and hotel costs are not included.


  • Merck & Co.: Roundtable meetings will be held on the main campus at 2000 Galloping Hill Road, Kenilworth, NJ 07033
    - Keynote reception and dinner at the Galloping Hill Golf Course, a 5 min. drive or shuttle ride from Merck.
  • BlackRock: The Investor Dialog will be held at 55 E 52nd St, New York, NY 10055.

Hotel: We have reserved a room block at a special discount rate for the two-day Roundtable at Merck:

  • Kenilworth Inn, 60 South 31st Street, Kenilworth, NJ 07033
  • Reservations: Call +1-908-241-4100, and mention the Biopharma Sustainability Roundtable
  • The special Group Rate of $129.00 USD per night is only available until March 8th, so please make your reservations soon!
  • Ask about the complimentary shuttle service from EWR if you're flying in.

We have not organized a special room block in NYC as there are so many mid-town options available.


Who can I contact with any questions?

US: Sandor Schoichet, Director, Meridian Management Consultants
sschoichet@meridianmc.com | +1 415 828 1302 | PST

Europe: Thomas Scheiwiller, Independent Advisor, Impacts
thomas@scheiwiller-impacts.com | +41 79 610 8112 | CET

Does PayPal take credit cards (MC, Visa, AmEx) and corporate P-cards?

Yes. Click on the "Check Out with PayPal" button, then click on the text link "Don't have a PayPal account?" It's right beneath the PayPal login box, and opens a standard credit card payment screen.

Can I request an invoice for off-line payment?

Yes. Click on the link "Show Other Payment Options" right beneath the big "Registration" button. Click the new "Pay Offline" button to complete your registration and have an invoice emailed to you. Net payment is due 15 days after registration.

Is my registration transferrable?

Yes. Your registration can be used by another appropriate participant from your organization, though we would appreciate hearing about any changes in advance of the meeting.

What is the refund policy?

Roundtable and Investor Dialog registration fees are 50% refundable through March 8, 2019. Registration fees are not refundable after March 8th.

All Rights Reserved | © 2018-19 Meridian Management Consultants LLC

Share with friends

Date and Time


Merck & Co.

2000 Galloping Hill Road

Kenilworth, NJ 07033

View Map

Refund Policy

Refunds up to 30 days before event

Save This Event

Event Saved